Dynamic measurement and implication of markers of chronic hepatitis in patients treated with Telbivudine

Objective To observe the therapeutic efficacy of telbivudine treatment on chronic hepatitis B. Methods Eighty-three patients,who were given with 48 weeks telbivudine treatment for the first time,were divided into HBeAg negative group(40 cases) and positive group(43 cases).HBV DNA,ALT level,HBV biomarkers were examined at baseline,4th,12th,24th and 48th week.HBV DNA conversion rate,ALT normalization rate,HBeAg conversion rate and seroconversion rate(HBV-M conversion ratio) were analyzed. Results In HBeAg negative group,the HBV DNA conversion rates were 25%,47%,77.5% and 87.50%,at the 4th,12th,24th and 48th week,respectively;while the ALT normalization rates were 5%,55%,80% and 97.5%,respectively.Meanwhile,in HBeAg positive group,the HBV DNA conversion rates were 2.3%,16.3%,48.8% and 67.4%,respectively,at the 4th,12th,24th and 48th week;while the ALT normalization rates were 2.3%,51.2%,79.1% and 93.0%,respectively;and the HBeAg conversion rates were 0,16.3%,32.6% and 48.8%,respectively;and the seroconversion rate were 0,11.63,18.60 and 34.88%,respectively. Conclusion Telbivudine effectively inhibits replication of hepatitis B virus,improves HBV DNA conversion,and promotes decline of ALT.In addition,higher efficacy on HBV DNA conversion wtih telbivudine treatment is found in HBeAg negative patients.